Bristol-Myers shares jumped 3% yesterday after a late-stage study on cancer drug Opdivo proved to be a success, leading to Deutsche Bank raising its price target on the company’s stock
Bristol-Myers Squibb Co (NYSE:BMY) shares rallied 3% to close at $62.18 apiece yesterday, hitting a new 52-week high, after a late-stage study on the company’s cancer drug Opdivo was successful in meeting its primary endpoint.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch16
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft8
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16